Corbus Pharmaceuticals Holdings Inc (CRBP)

NASDAQ:
CRBP
| Latest update: May 3, 2026, 5:36 PM

Stock events for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Over the past six months, Corbus announced a proposed public offering, presented data for CRB-701 at the ESMO Congress, completed a Phase 1a study for CRB-913, and participated in healthcare conferences. They also reported Q4 and full-year 2025 financial results and announced alignment with the FDA on the registration path for CRB-701. The stock price has seen significant movement, with a 94.63% increase between April 7, 2025, and April 6, 2026. Over the last 12 months, the stock's price increased by 80.15%, and in the past month, it increased by 21.07%. However, over the past six months, the stock has experienced a -52.33% change.

Demand Seasonality affecting Corbus Pharmaceuticals Holdings, Inc.’s stock price

As a clinical-stage biopharmaceutical company, Corbus Pharmaceuticals does not experience demand seasonality in the traditional sense, as its products are still in development and not yet commercialized.

Overview of Corbus Pharmaceuticals Holdings, Inc.’s business

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious illnesses, particularly oncology and obesity. Their pipeline includes CRB-701, an antibody-drug conjugate for Nectin-4-expressing tumors; CRB-601, an anti-integrin monoclonal antibody; and CRB-913, a CB1 receptor inverse agonist for obesity.

CRBP’s Geographic footprint

Corbus Pharmaceuticals Holdings, Inc. is headquartered in Norwood, Massachusetts, United States. Clinical studies for product candidates like CRB-701 have included participants from both the U.S. and Europe.

CRBP Corporate Image Assessment

Corbus Pharmaceuticals' brand reputation has been influenced by its clinical trial progress and financial updates. Positive data readouts for CRB-701 and CRB-913, along with FDA alignment for CRB-701, contribute positively. Analyst ratings, such as Mizuho Securities' "Buy" rating, suggest a positive outlook.

Ownership

Corbus Pharmaceuticals Holdings, Inc. is owned by a mix of institutional shareholders and insiders. Institutional ownership stands at 74.67%, while insiders own 83.21%. Major institutional owners include Cormorant Asset Management, LP, Orbimed Advisors LLC, and Vanguard Group Inc. Cormorant Asset Management LP is the largest individual shareholder, owning 26.61% of the company.

Price Chart

$10.30

4.25%
(1 month)

Top Shareholders

Cormorant Asset Management LP
13.36%
OrbiMed Advisors LLC
9.10%
Aberdeen Group Plc
7.53%
Octagon Capital Advisors LP
5.44%
The Vanguard Group, Inc.
4.90%
GFH HFEVA LLC
4.80%
Prosight Management LP
3.90%
Armistice Capital LLC
3.05%

Trade Ideas for CRBP

Today

Sentiment for CRBP

News
Social

Buzz Talk for CRBP

Today

Social Media

FAQ

What is the current stock price of Corbus Pharmaceuticals Holdings, Inc.?

As of the latest update, Corbus Pharmaceuticals Holdings, Inc.'s stock is trading at $10.30 per share.

What’s happening with Corbus Pharmaceuticals Holdings, Inc. stock today?

Today, Corbus Pharmaceuticals Holdings, Inc. stock is up by 4.25%, possibly due to news.

What is the market sentiment around Corbus Pharmaceuticals Holdings, Inc. stock?

Current sentiment around Corbus Pharmaceuticals Holdings, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Corbus Pharmaceuticals Holdings, Inc.'s stock price growing?

Over the past month, Corbus Pharmaceuticals Holdings, Inc.'s stock price has increased by 4.25%.

How can I buy Corbus Pharmaceuticals Holdings, Inc. stock?

You can buy Corbus Pharmaceuticals Holdings, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol CRBP

Who are the major shareholders of Corbus Pharmaceuticals Holdings, Inc. stock?

Major shareholders of Corbus Pharmaceuticals Holdings, Inc. include institutions such as Cormorant Asset Management LP (13.36%), OrbiMed Advisors LLC (9.10%), Aberdeen Group Plc (7.53%) ... , according to the latest filings.